1. Home
  2. LOCL vs TVRD Comparison

LOCL vs TVRD Comparison

Compare LOCL & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Local Bounti Corporation

LOCL

Local Bounti Corporation

HOLD

Current Price

$2.57

Market Cap

25.6M

ML Signal

HOLD

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$3.15

Market Cap

29.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOCL
TVRD
Founded
2021
2017
Country
United States
United States
Employees
333
12
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.6M
29.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LOCL
TVRD
Price
$2.57
$3.15
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
2.1M
48.4K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$97.19
N/A
Revenue Next Year
$33.69
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.98
$2.75
52 Week High
$4.00
$43.65

Technical Indicators

Market Signals
Indicator
LOCL
TVRD
Relative Strength Index (RSI) 68.52 48.65
Support Level $2.20 $2.75
Resistance Level $2.75 $3.50
Average True Range (ATR) 0.26 0.23
MACD 0.10 0.02
Stochastic Oscillator 68.85 55.22

Price Performance

Historical Comparison
LOCL
TVRD

About LOCL Local Bounti Corporation

Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: